About Us

Since its founding in 2013 in the Finger Lakes higher education corridor, Ichor has studied fundamental mechanisms of aging to develop new classes of drugs dedicated to helping people live longer, healthier lives.

Building a successful company is a consequence of what we do in the pursuit of our vision. We are intrinsically motivated to create positive change in the world because we believe we can.

Our History

May, 2013

Hello world!

Ichor is founded in living room apartment.

November, 2014

Lysoclear launches.

Ichor moves to LaFayette and starts Lysoclear.

March, 2016

Antoxerene/FoxBio launches.

Ichor purchases second commercial site. Antoxerene/FoxBio founded.

February, 2017

Ichor acquires Finger Lakes Bio.

Ichor acquires boutique protein engineering company Finger Lakes Bio.

May, 2018

Auctus launches.

Ichor launches Auctus. All programs fully funded with new investment rounds.

August, 2020

Ichor acquires Woodland.

Ichor acquires oncology and metabolic disease CRO Woodland Biosciences.

July, 2021

Ichor rebrands as Ichor Life Sciences.

Ichor Therapeutics rebrands as Ichor Life Sciences to emphasize service offerings.


IMG_100055 (48)
Kelsey Moody, PhD, MBA
Chief Executive Officer
Aaron Wolfe, PhD
Chief Science Officer

Our Team

Team is the foundation of Ichor, and we invest heavily in employee recruitment, training, and advancement.

High school and undergraduate students can engage the company through our internship program. Graduates can explore career opportunities at the company. Employees interested in higher education can enroll in our PhD program after working at least 1 year for the company.

We work towards a vision, not for a company

Building a successful company is a consequence of what we do in the pursuit of our vision. We are intrinsically motivated to create positive change in the world, and this philosophy extends to all aspects of company operations.

At our core, we are committed to delivering the next generation of pharmaceuticals. Our burden of proof is to make products that work. We eagerly take on this challenge every day in the laboratory.

We are friends

We are friends on and off the job. Staff regularly participate in group runs, paintball, gaming, and night life.

We are community

We work to make a difference because we believe we can. we are a part of the communities that we serve.

We are people

Every photo on our website came from our laboratory. We are true to the lives we hope to extend.

We issue Nerf guns

Work hard. Play hard.

We build our own talent

Fundamental to the Ichor culture is an emphasis on professional development. Our team is not only evaluated on what they already know, but also on an ability to obtain new skills, work through diverse challenges, and anticipate and preempt complications within company workflows. Team members are encouraged to embrace professional development opportunities, and to obtain cross training in areas unrelated to their core competencies.

Unconventional thinking.

Unprecedented doing.

Our Story

Today Ichor is a vertically integrated contract research organization occupying multiple commercial facilities with complete pre-clinical R&D capabilities in LaFayette, NY and Potsdam, NY. However, the company’s beginnings were far more modest.

Ichor was founded in 2013 by Kelsey Moody during his time as a medical student at SUNY Upstate Medical University in Syracuse, NY. Using a $540k seed grant awarded by the Life Extension Foundation, Ichor established a functional living room laboratory in historic Tipperary Hill.

The living room laboratory was equipped for biological research. Initial programs at the company focused on stem cell biology, which required capabilities to support mammalian cell culture, flow cytometry and fluorescence microscopy.

Working with his father, a retired math teacher and contractor, Dr. Moody and company constructed a specific-pathogen free vivarium suitable for research with immunocompromised mice in the apartment’s spare bedroom. This enabled advanced husbandry capabilities at the company, including xenograft models.

In 2014, the Ichor team solved a series of technical problems that had prevented further development of SENS Foundation’s macular degeneration enzyme therapy program (which would later become Lysoclear) and acquired all rights to the program.

With over $1 million in new funding led by Ichor’s first major investor and partner Roger Bagg, multiple research programs in progress, and a growing client base for contract research, Ichor relocated south of Syracuse to rural LaFayette and established its first commercial research facilities.

Since these humble beginnings, Ichor has risen to prominence as a premier provider of contract laboratory services. The company’s strong publication record and PhD program are a testament to the quality standard for scientific excellence that defines Ichor.

Today, with a research team occupying multiple facilities in LaFayette and Potsdam, Ichor continues its ambitious pursuit of excellence in integrated drug discovery.

Ichor start-up (2013)
Ichor living room lab (2013)
Ichor living room lab (2013)
Ichor research lab (2018)
Ichor research lab (2018)
Ichor 3rd vivarium (2018)
Ichor research lab (2018)
Ichor research lab (2018)
Ichor research lab (2018)